Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery

Journal of Microencapsulation

Volumn 27, Issue 1, 2010, Pages 37-47

  Başaran, Ebru ^a   Demirel, Müzeyyen ^a   Sirmagül, Başar ^b   Yazan, Yasemin ^a  

^a ANADOLU UNIVERSITY   (Turkey)

^b ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Cationic solid lipid nanoparticles; Cyclosporine A; Ocular application

Indexed keywords

CATION; CYCLOSPORIN A; SOLID LIPID NANOPARTICLE; CYCLOSPORIN; DELAYED RELEASE FORMULATION; EYE DROPS; IMMUNOSUPPRESSIVE AGENT; LIPID; NANOPARTICLE;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; ENZYME IMMUNOASSAY; EYE; IN VIVO STUDY; INDIVIDUALITY; INTRAOCULAR DRUG ADMINISTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SHEEP; VETERINARY MEDICINE; VITREOUS BODY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFERENTIAL SCANNING CALORIMETRY; INFRARED SPECTROSCOPY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; X RAY DIFFRACTION;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; CATIONS; CYCLOSPORINE; DELAYED-ACTION PREPARATIONS; EYE; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; NANOPARTICLES; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; SHEEP; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 75449109191     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652040902846883     Document Type: Article

References (29)

1. Abdulrazik M, Tamilvanan S, Khoury K, Benita S. 2001. Ocular delivery of cyclosporin A II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A. STP Pharm Sci 11:427-432.
2. Amini H, Ahmadiani A. 2003. Simple determination of cyclosporine in human whole blood by high-performance liquid chromatograpy. J Chromatogr B 795:209-214.
3. Attama AA, Reichl S, Müller-Goymann CC. 2008. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 355:307-313.
4. Bunjes H, Unruh T. 2007. Characterization of lipid nanoparticles by differential scanning calorimetry, x-ray and neutron scattering. Adv Drug Deliv Rev 59:379-402.
5. CEDIA-. 2006. Cyclosporine PLUS Assay Specification Sheet. Fremont, VA: Microgenics Corporation.
6. Cengiz E, Wissing SA, Mü ller RH, Yazan Y. 2006. Sunblocking efficiency of various TiO2-loaded solid lipid nanoparticle formulations. J Cosmet Sci 28:371-378.
7. Choc G. 2000. Cyclosporine: Pharmacology. In: Yocum DE, editor. Cyclosporine. Clinical application in autoimmune diseases. Philadelphia, PA: Harcourt Health Communications. pp 15-29.
8. Demirel M, Yazan Y. 2000. Kat lipid nanopartikü ller (SLN). FABAD 25:167-179.
9. Fang J-Y, Fang C-L, Liu C-H, Su Y-H. 2008. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. Pharm Biopharm 70:633-640.
10. Gürsoy AZ. 2002. Okü ler sistemler. In: Gürsoy AZ, editor. Kontrollü Salm Sistemleri. -Istanbul: Elma Bilgisayar Basm ve Ambalaj San.Tic.Ltd.şti. pp 197-217.
11. Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari F, Güneri T, et al.. 2008. Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 364:76-86.
12. Hirunpanich V, Sugiyama E, Sato H. 2008. Ethyl docosahexaenoate decreased Neoral- absorption due to particle size enlargement. Int J Pharm 361:251-252.
13. Jenning V, Mäder K, Gohla SH. 2000. Solid lipid nanoparticles (SLNTM) based on binary mixtures of liquid and solid lipids: A 1H-NMR study. Int J Pharm 205:15-21. (Pubitemid 30734720)
14. Jenning V, Thünemann AF, Gohla SH. 2000. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167-177. (Pubitemid 30236188)
15. Kumar M, Singhal SK, Singh A. 2001. Development and validation of a stability indicating HPLC assay method for cyclosporine in cyclosporine oral solution USP. J Pharm Biomed Anal 25:9-14.
16. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. 2003. Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm 56:307-318.
17. Lallemand F, Felt-Baeyens O, Rudaz S, Hamel AR, Hubler F, Wenger R, et al.. 2005a. Conversion of cyclosporine A prodrugs in human tears vs rabbits tears. Eur J Pharm Biopharm 59:51-56. (Pubitemid 39573436)
18. Lallemand F, Furrer P, Felt-Baeyens O, Gex-Fabry M, Dumont JM, Besseghir K, et al.. 2005b. A novel water-soluble cyclosporine A prodrug: Ocular tolerance and in vivo kinetics. Int J Pharm 295:7-14. (Pubitemid 40558784)
19. Lee C-L, Jiang P-P, Sit W-H, Wan JM-F. 2007. Proteome of human T lymphocytes with treatment of cyclosporine and polysaccharopeptide: Analysis of significant proteins that manipulate T cells proliferation and immunosuppression. Int Immunopharm 7:1311-1324.
20. Li Y, Wong HL, Shuhendler AJ, Rauth AM, Yu Wu X. 2008. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J Contr Rel 128:60-70.
21. Mü ller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161-177.
22. Mü ller RH, Runge SA, Ravelli V. 2008. Thünemann AF, Mehnert W, Souto EB. 2008. Cyclosporine-loaded solid lipid nanoparticles (SLN-): Drug- lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 68:535-544.
23. Mü ller RH, Runge SA, Ravelli V, Mehnert W, Thünemann AF, Souto EB. 2006. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN-) versus drug nanocrystals. Int J Pharm 317:82-89.
24. Manjunath K, Reddy JS, Venkateswarlu V. 2005. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 27:127-144.
25. Olbrich C, Kayser O, Mü ller RH. 2002. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of surfactants, storage period and crystallinity. Int J Pharm 237:119-128.
26. Radomska-Soukharev A. 2007. Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev 59:411-418.
27. Siekmann B, Westesen K. 1994. Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Coll Surf B Bioint 3:159-175.
28. Tamilvanan S, Benita S. 2004. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm 58:357-368.
29. Tamilvanan S, Khoury K, Gilhar D, Benita S. 2001. Ocular delivery of cyclosporin A I. design and characterization of cyclosporin A-loaded positively-charged submicron emulsion. STP Pharm Sci 11:421-426.